Physician profile
Michael Montgomery
NPI 1659340990
$640.48
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $526 · 2020: $114.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $169.94 | 2019 | |
| Novo Nordisk INC | $44.71 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $42.91 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.79 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $35.94 | 2019 | |
| Antares Pharma, INC. | $35.15 | 2019 | |
| Novartis Pharmaceuticals Corporation | $35.02 | 2019-2020 | |
| Sanofi Pasteur INC. | $28.30 | 2019-2020 | |
| Astellas Pharma US INC | $27.51 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $26.01 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.19 | 2019 | |
| Janssen Pharmaceuticals, INC | $24.53 | 2019 | |
| Pfizer INC. | $19.90 | 2019 | |
| Amarin Pharma, INC. | $15.20 | 2019 | |
| Currax Pharmaceuticals LLC | $14.76 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $14.50 | 2019 | |
| Glaxosmithkline, LLC. | $13.60 | 2019 | |
| Zyla Life Sciences, INC. | $13.03 | 2019 | |
| Amgen INC. | $12.49 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Montgomery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.